A Phase I study of a prolonged infusion of triapine in combination with a fixed dose rate of gemcitabine in patients with advanced solid tumors and lymphomas.

Trial Profile

A Phase I study of a prolonged infusion of triapine in combination with a fixed dose rate of gemcitabine in patients with advanced solid tumors and lymphomas.

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Jan 2016

At a glance

  • Drugs OCX 191 (Primary) ; Gemcitabine
  • Indications Anaplastic large cell lymphoma; Burkitt's lymphoma; Diffuse lymphoma; Follicular lymphoma; Hodgkin's disease; Lymphoid leukaemia; Lymphoma; Mantle-cell lymphoma; Mycosis fungoides; Non-Hodgkin's lymphoma; Solid tumours; Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 27 Sep 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 27 Sep 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 04 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top